Signet and Bayer in inflammatory disease pact
This article was originally published in Clinica
Executive Summary
US diagnostic/research firm Signet Laboratories has formed a pact with Bayer Diagnostics to conduct research into inflammatory-based diseases using the latter's urinary trypsin inhibitor immunoassays. The Dedham, Massachusetts firm has licensed the immunoassays, which were discovered by Bayer scientists and which detect two markers of inflammation, uristatin and bikunin, in blood and urine.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.